Evidence map›Paper›PMID 31276932›Full record

ArticleNeoplasia (New York, N.Y.)2019

Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.

Jae-Seung Chung, Yugang Wang, James Henderson, Udit Singhal, Yuanyuan Qiao, Alexander B Zaslavsky, Daniel H Hovelson, Daniel E Spratt, Zachery Reichert, Ganesh S Palapattu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Jae-Seung ChungDepartment of Urology, University of Michigan, Ann Arbor, MI, USA; Department of Urology, Inje University, Haeundae Paik Hospital, Busan, Republic of Korea.
Yugang WangDepartment of Urology, University of Michigan, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
James HendersonDepartment of Urology, University of Michigan, Ann Arbor, MI, USA; Consulting for Computing, Statistics, and Analytics Research (CSCAR), University of Michigan, Ann Arbor, MI, USA.
Udit SinghalDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Yuanyuan QiaoMichigan Center for Translational Pathology, Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Alexander B ZaslavskyDepartment of Urology, University of Michigan, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Daniel H HovelsonMichigan Center for Translational Pathology, Department of Pathology, University of Michigan, Ann Arbor, MI, USA; Department of Computational Medicine and Bioinformatics, Michigan Medicine, Ann Arbor, MI, USA.
Daniel E SprattUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Radiation Oncology, Michigan Medicine, Ann Arbor, MI, USA.
Zachery ReichertDepartment of Hematology/Oncology, University of Michigan, Ann Arbor,MI, USA.
Ganesh S PalapattuDepartment of Urology, University of Michigan, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Urology, Medical University of Vienna, Vienna, Austria.
Russell S TaichmanDepartment of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, University of Michigan, Ann Arbor, MI, USA.
Scott A TomlinsDepartment of Urology, University of Michigan, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Todd M MorganDepartment of Urology, University of Michigan, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. Electronic address: tomorgan@med.umich.edu.
University of Michigan–Ann Arbor · USMichigan Center for Translational Pathology · USInje University Haeundae Paik Hospital · KRMichigan Medicine · US

Funding

Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
NCI NIH HHS T32 CA180984
6 · The paper itself

Abstract

While circulating tumor cell (CTC)-based detection of AR-V7 has been demonstrated to predict patient response to second-generation androgen receptor therapies, the rarity of AR-V7 expression in metastatic castrate-resistant prostate cancer (mCRPC) suggests that other drivers of resistance exist. We sought to use a multiplex gene expression platform to interrogate CTCs and identify potential markers of resistance to abiraterone and enzalutamide. 37 patients with mCRPC initiating treatment with enzalutamide (n = 16) or abiraterone (n = 21) were prospectively enrolled for CTC collection and gene expression analysis using a panel of 89 prostate cancer-related genes. Gene expression from CTCs was correlated with PSA response and radioclinical progression-free survival (PFS) using Kaplan-Meier and Cox regression analyses. Twenty patients (54%) had detectable CTCs. At a median follow-up of 11.3 months, increased expression of the following genes was significantly associated with shorter PSA PFS and radioclinical PFS: AR, AR-V7, PSA, PSCA, TSPAN8, NKX3.1, and WNT5B. Additionally, high SPINK1 expression was associated with increased PFS. A predictive model including all eight genes gave an area under the curve (AUC) of 0.84 for PSA PFS and 0.86 for radioclinical PFS. In comparison, the AR-V7 only model resulted in AUC values of 0.65 and 0.64.These data demonstrate that clinically relevant information regarding gene expression can be obtained from whole blood using a CTC-based approach. Multigene classifiers in this setting may allow for the development of noninvasive predictive biomarkers to guide clinical management.

Indexed as

Biomarkers, TumorAgedAged, 80 and overAndrostenesAntineoplastic Combined Chemotherapy ProtocolsBenzamidesComputational BiologyDrug Resistance, NeoplasmGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingabirateroneAndrostenesBenzamidesBiomarkers, TumorenzalutamideNitrilesPhenylthiohydantoin

Identifiers

PMID31276932
PMCPMC6612010
OpenAlexW2954242906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.